Fulcrum Therapeutics (FULC) Capital Expenditures (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Capital Expenditures data on file, last reported at $8000.0 in Q1 2026.

• Capital Expenditures for Q1 2026 came in at $8000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $322000.0 (up 28.8% YoY), and the FY2025 annual result was $314000.0, up 12.95% from the prior year.
• Capital Expenditures fell to $8000.0 in Q1 2026 per FULC's latest filing, from $155000.0 in the prior quarter.
• Over five years, Capital Expenditures peaked at $1.3 million in Q2 2022 and troughed at -$1.8 million in Q4 2022.
• A 5-year average of $75600.0 and a median of $98000.0 in 2024 frame the typical range for Capital Expenditures.
• The sharpest annual moves came in 2022 and 2024: Capital Expenditures soared 515.0% in 2022, then sank 103.14% in 2024.
• A 5-year view of Capital Expenditures shows it stood at -$1.8 million in 2022, then soared by 104.23% to $77000.0 in 2023, then advanced by 27.27% to $98000.0 in 2024, then jumped by 58.16% to $155000.0 in 2025, then sank by 94.84% to $8000.0 in 2026.
• Business Quant data shows FULC's Capital Expenditures at $8000.0 in Q1 2026, $155000.0 in Q4 2025, and $159000.0 in Q3 2025.